Relation of Dietary Salt and Aldosterone to Urinary Protein Excretion in Subjects With Resistant Hypertension

Eduardo Pimenta, Krishna K. Gaddam, Monique N. Pratt-Ubunama, Mari K. Nishizaka, Inmaculada Aban, Suzanne Oparil, David A. Calhoun

Abstract—Experimental data indicate that the cardiorenal effects of aldosterone excess are dependent on concomitant high dietary salt intake. Such an interaction of endogenous aldosterone and dietary salt has not been observed previously in humans. We assessed the hypothesis that excess aldosterone and high dietary sodium intake combine to worsen proteinuria in patients with resistant hypertension. Consecutive subjects with resistant hypertension (n=84) were prospectively evaluated by measurement of 24-hour urinary aldosterone (Ualdo), sodium, and protein (Uprot) excretion. Subjects were analyzed according to aldosterone status (high: Ualdo ≥12 μg/24 hours; or normal: <12 μg/24 hours) and dietary salt intake based on tertiles of urinary sodium. The mean clinic blood pressure for all of the subjects was 161.4±22.4/89.8±13.5 mm Hg on an average of 4.3 medications. There was no blood pressure difference between study groups. Uprot was significantly higher in the 38 subjects with high Ualdo compared with the 46 subjects with normal Ualdo (143.0±83.8 versus 95.9±81.7 mg/24 hours; P=0.01). Among subjects with high Ualdo, Uprot increased progressively across urinary sodium groups (P<0.05). In contrast, there was no difference in Uprot across sodium tertiles among subjects with normal Ualdo. A positive correlation between Uprot and urinary sodium (r=0.47; P=0.003) was observed in subjects with high Ualdo but not in subjects with normal Ualdo (r=0.18; P value not significant). These results suggest that aldosterone excess and high dietary salt combine to increase urinary protein excretion. (Hypertension. 2008;51:339-344.)

Key Words: hypertension ▪ aldosterone ▪ salt ▪ proteinuria ▪ kidney

Aldosterone excess is being increasingly recognized as a common cause of hypertension, with recent reports indicating a prevalence of primary aldosteronism (PA) of 5% to 10% among general hypertensive patients. Among patients with resistant hypertension, PA is even more common, with a prevalence of ~20%. Animal models indicate that aldosterone excess, in addition to increasing blood pressure (BP), contributes directly to target-organ (heart, brain, and kidney) deterioration by inducing inflammation and perivascular fibrosis. These same studies have been consistent in demonstrating that the presor, proinflammatory, and profibrotic effects of aldosterone are dependent on concomitant high dietary salt intake. Whether such an interaction between aldosterone and dietary salt occurs in humans is unknown.

Increases in intracapillary pressure, structural damage of the glomerular membrane, and impaired endothelial function likely contribute to the development of albuminuria and proteinuria in hypertensive patients. Proteinuria is an early sign of nephropathy associated with progressive glomerulosclerosis, tubulointerstitial inflammation, and scarring, with progressive renal function loss in both diabetic and nondiabetic subjects. Proteinuria is also independently associated with increases in cardiovascular risk.

The present study was designed to evaluate the effects of endogenous aldosterone and dietary salt, separately and in combination, on proteinuria in subjects with resistant hypertension. In enrolling subjects with resistant hypertension, we were purposefully selecting a cohort known to be at high risk for hyperaldosteronism.

Methods

Subjects
Consecutive subjects referred to the University of Alabama at Birmingham Hypertension Clinic for resistant hypertension were prospectively evaluated. The protocol was approved by the University of Alabama at Birmingham Institutional Review Board for Human Use, and all of the subjects provided written informed consent before study participation. Resistant hypertension was defined as uncontrolled hypertension (>140/90 mm Hg) determined at ≥2 clinic visits despite the use of ≥3 antihypertensive medications at pharmacologically effective doses. All of the subjects were on a stable antihypertensive regimen for ≥4 weeks before biochemical evaluation. No medications were discontinued before evaluation except for spironolactone, triamterene, or amiloride, which were discontinued for ≥6 weeks before evaluation.

Received August 29, 2007; first decision September 19, 2007; revision accepted November 16, 2007.
From the Vascular Biology and Hypertension Program, University of Alabama at Birmingham.
Correspondence to Eduardo Pimenta, 933 19th St South, Room 115, Birmingham, AL 35294. E-mail eduardo.pimenta@ccc.uab.edu
© 2008 American Heart Association, Inc.

Hypertension is available at http://hyper.ahajournals.org

DOI: 10.1161/HYPERTENSIONAHA.107.100701

339
Table. Demographic and Biochemical Values for All of the Subjects and for Subjects Divided by High and Normal Ualdo

<table>
<thead>
<tr>
<th>Parameter</th>
<th>All Subjects (n=84)</th>
<th>High Ualdo (n=38)</th>
<th>Normal Ualdo (n=46)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Males, %</td>
<td>46.4</td>
<td>63.2</td>
<td>32.6</td>
</tr>
<tr>
<td>African Americans, %</td>
<td>41.6</td>
<td>39.5</td>
<td>43.4</td>
</tr>
<tr>
<td>Age, y</td>
<td>55.1±10.5</td>
<td>54.9±10.2</td>
<td>55.3±10.9</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>33.7±7.1</td>
<td>34.1±7.9</td>
<td>33.4±6.4</td>
</tr>
<tr>
<td>Duration of HTN, y</td>
<td>15.2±9.9</td>
<td>15.3±8.6</td>
<td>15.2±11.0</td>
</tr>
<tr>
<td>No. of medicines</td>
<td>4.3±1.1</td>
<td>4.4±1.2</td>
<td>4.3±1.0</td>
</tr>
<tr>
<td>Serum potassium, mEq/L</td>
<td>4.0±0.4</td>
<td>4.0±0.5</td>
<td>4.0±0.3</td>
</tr>
<tr>
<td>PAC, ng/dL</td>
<td>11.1±7.6</td>
<td>14.4±9.0</td>
<td>8.3±4.8‡</td>
</tr>
<tr>
<td>PRA, ng/mL/h</td>
<td>3.4±6.5</td>
<td>2.2±3.5</td>
<td>4.4±8.1</td>
</tr>
<tr>
<td>ARR</td>
<td>14.1±17.1</td>
<td>15.7±13.6</td>
<td>8.3±8.7*</td>
</tr>
<tr>
<td>UNa, mEq/24 h</td>
<td>172.3±74.8</td>
<td>177.3±70.2</td>
<td>168.2±78.8</td>
</tr>
<tr>
<td>CrCl, mL/min</td>
<td>105.8±34.7</td>
<td>123.4±32.6</td>
<td>100.0±26.8†</td>
</tr>
<tr>
<td>Uprot, mg/24 h</td>
<td>119.9±87.7</td>
<td>143.0±83.8</td>
<td>95.9±81.7*</td>
</tr>
<tr>
<td>Office BP, mm Hg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>161.4±22.4</td>
<td>160.2±22.5</td>
<td>159.4±22.7</td>
</tr>
<tr>
<td>Diastolic</td>
<td>89.8±13.5</td>
<td>92.1±14.0</td>
<td>87.1±13.6</td>
</tr>
</tbody>
</table>

BMI indicates body mass index; HTN, hypertension; ARR, PAC/PRA ratio. *P<0.01 compared to high-Ualdo. †P<0.001 compared to high-Ualdo. ‡P<0.0001 compared to high-Ualdo.

The office BP was measured after having the subject sit for ≥5 minutes with a mercury sphygmomanometer according to American Heart Association guidelines. Secondary causes of hypertension other than hyperaldosteronism, such as renovascular hypertension, pheochromocytoma, or Cushing’s syndrome, were excluded by laboratory analysis and/or radiological imaging as clinically indicated. Subjects with a history of atherosclerotic disease (myocardial infarction or stroke <6 months), congestive heart failure, current smoking, diabetes on insulin treatment, or urine protein excretion >300 mg/24 hours were excluded from study participation.

Laboratory Assessment

Biochemical evaluation was done in all of the subjects on an outpatient basis. An early morning plasma aldosterone concentration (PAC):plasma renin activity (PRA) ratio (ARR), serum potassium, and creatinine were determined in ambulatory patients after sitting for 5 minutes. A 24-hour urinary collection for aldosterone (Ualdo), sodium (UNa), protein (Uprot), and creatinine was obtained during the subject’s routine diet.

PAC, PRA, Ualdo, UNa, and Uprot were measured by commercial laboratories using standard techniques. PAC, PRA, and UNa levels were measured by radioimmunoassay (Quest Diagnostics for PAC and PRA; Mayo Clinic Laboratories for Ualdo). Creatinine clearance (CrCl) was calculated from the serum creatinine and the 24-hour urinary excretion of creatinine.

Statistical Analysis

Subjects were divided into 2 groups according to Ualdo (normal: <12 μg/24 hours; or high: ≥12 μg/24 hours) and into 3 groups according to tertiles of UNa. The cutoff value of Ualdo ≥12 μg/24 hours was chosen to separate the high- and normal-aldosterone groups consistent with current recommendations for diagnosing PA. Values are expressed as mean±SD unless stated otherwise. Demographic characteristics between the Ualdo groups were compared using t tests for continuous variables and Fisher’s exact test for categorical variables.

Results

A total of 84 subjects were evaluated. Thirty eight of the subjects had high Ualdo and 46 had normal Ualdo (Table). Overall, subjects were on an average of 4.3±1.1 medications, with a mean office BP of 161.4±22.4/89.8±13.5 mm Hg. Both the numbers and types of antihypertensive medications used were the same in each of the Ualdo-UNa groups. Patients within the high-Ualdo group had significantly higher PAC, ARR, and CrCl levels. PRA, UNa, and systolic and diastolic BP did not differ between groups. Uprot was significantly higher in high-Ualdo compared with normal-Ualdo subjects (Figure 1).

Ualdo, PRA, and office systolic and diastolic BPs were similar across sodium groups in both the high- and normal-Ualdo subjects. Within the high-Ualdo group, Uprot was significantly higher in the third compared with the first tertile of UNa (Figure 2). In contrast, within the normal-Ualdo group, Uprot tended to increase across tertiles of UNa, but differences were not significant. A positive and strong correlation (r=0.468; P=0.003) between the Uprot and UNa was present in high-Ualdo subjects but not in normal-Ualdo subjects (r=0.183; P=0.223; Figure 3, top). CrCl was sig-
significantly correlated with Uprot in high-Ualdo ($r=0.414; P=0.012$) and normal-Ualdo ($r=0.302; P=0.043$) subjects (Figure 3, middle). CrCl was significantly correlated with UNa ($r=0.529; P=0.001$) in high-Ualdo but not in normal-Ualdo subjects ($r=0.245; P=0.105$; Figure 3, bottom).

**Discussion**

The current results demonstrate that, in patients with resistant hypertension and hyperaldosteronism, increasing dietary salt ingestion is associated with progressive worsening of proteinuria. Previous studies in humans have indicated that hyperaldosteronism and high dietary salt independently contribute to increased proteinuria. The current study extends these results by suggesting that aldosterone excess and high salt ingestion, in combination, further worsen proteinuria in subjects with resistant hypertension. These results are consistent with a large body of experimental data demonstrating that high dietary salt interacts with aldosterone excess to accelerate target-organ damage.

Previous human studies have demonstrated that aldosterone excess and increasing dietary salt ingestion separately contribute to the development of proteinuria. In a large cross-sectional analysis of 2700 participants, Framingham investigators showed that high dietary salt intake was significantly related to urinary albumin excretion. Albuminuria was 2-fold higher in the highest quintile of urinary sodium excretion compared with the lowest. In this cohort, the highest quintile of serum aldosterone levels was associated with a 21% higher level of urinary albumin excretion compared with the lowest quintile. In this analysis of largely normotensive subjects, the investigators did not find that high plasma aldosterone levels combined with high urinary sodium excretion to worsen albuminuria. The Framingham results are consistent with other studies linking increasing dietary salt ingestion to increases in urinary albumin/protein excretion.

Several observational studies have shown that subjects with PA have higher levels of urinary protein excretion compared with subjects with primary hypertension. The Primary Aldosteronism Prevalence in Hypertensives Study prospectively determined urinary albumin excretion in 490 hypertensive subjects, 64 of whom were confirmed to have PA. Subjects with PA, regardless of whether secondary to an
aldosterone-producing adenoma or presumed idiopathic hyperaldosteronism, had higher 24-hour urinary albumin excretion rates than subjects with primary hypertension.\textsuperscript{24} Ribstein et al\textsuperscript{26} reported higher urinary excretion of protein in 25 subjects with PA compared with control subjects with primary hypertension. In this study, the PA subjects were followed for 6 months after adrenalectomy or spironolactone treatment. There was a significant decrease in proteinuria with treatment of the aldosterone excess consistent with the interpretation that aldosterone directly or indirectly contributed to renal damage. Previous studies have not directly evaluated a potential interaction between hyperaldosteronism and various levels of dietary salt intake.\textsuperscript{28}

The pathological processes by which aldosterone and high dietary salt promote proteinuria are undoubtedly multifactorial.\textsuperscript{29} First, aldosterone excess through sodium and fluid retention increases BP, which, in turn, would contribute directly to target-organ damage, including the development of proteinuria. Second, aldosterone has known effects on renal hemodynamics that would promote the development of proteinuria. Specifically, aldosterone exerts a direct vasoconstrictive effect on the efferent renal arteriole and/or abolishes potassium chloride–induced vasorestrictive effect of the afferent arteriole.\textsuperscript{30,31} Such effects would combine to increase renal vascular resistance and glomerular capillary pressure, thereby promoting protein excretion. Lastly, animal models of hyperaldosteronism have clearly established a direct proinflammatory and profibrotic effect of aldosterone and high dietary salt on target-organ tissues.\textsuperscript{7,8}

Consistent with the current results, previous clinical studies suggest that aldosterone excess also promotes urinary protein excretion through the production of a hyperfiltration state.\textsuperscript{26,27} Sechi et al\textsuperscript{27} prospectively compared the renal function of 50 subjects with PA to subjects with primary hypertension matched for age, gender, body mass index, and estimated duration of hypertension. PA patients were followed for 6.4 years after treatment with adrenalectomy or aldosterone blockade. All of the classes of antihypertensive medications were allowed in primary hypertensive subjects to reach a goal of 140/90 mm Hg. In contrast to the current results, the Framingham Study cohort included a preponderance of normotensive persons in whom PA was presumably uncommon; aldosterone status was based on plasma sampling, and urinary sodium excretion was based on a spot urine collection.\textsuperscript{20} In the current analysis, the cohort consisted of subjects with resistant hypertension in whom aldosterone excess is common; aldosterone status was based on 24-hour urinary excretion, which provides a more integrated assessment of plasma secretion than plasma levels, and, lastly, urinary sodium excretion was based on a 24-hour collection.

Because the current study is observational, causality of the higher urinary protein excretion in the high aldosterone-high dietary salt group is not confirmed. However, urinary protein excretion and CrCl were significantly higher in the high compared with the normal aldosterone subjects, and both parameters increased in the high aldosterone subjects with increasing dietary salt intake. This suggests that aldosterone-induced intravascular fluid expansion and consequent increases in glomerular filtration rate (ie, hyperfiltration) may have contributed to the increased proteinuria. Such an effect is supported by studies reporting the antiproteinuric benefit of aldosterone blockade in association with significant reductions in the glomerular filtration rate.\textsuperscript{27,36,37}

The present study is strengthened by its prospective design and measurement of aldosterone, proteinuria, and sodium excretion by 24-hour urine collection. Study limitations include a cross-sectional design and having evaluated patients during ongoing antihypertensive treatment. Although biochemical evaluation is best done after the withdrawal of antihypertensive medications, this was not possible for safety reasons in these high-risk subjects. All of the subjects were on a stable antihypertensive regimen for $\geq 4$ weeks, such that their sodium balance should have been in steady state. Although antihypertensive medications predictably affect renin activity ($\beta$-blockers suppressing and diuretics, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers increasing), medication effects on aldosterone excretion are likely less pronounced, tending to have no effect on or to minimally reduce aldosterone secretion.\textsuperscript{38,39} Furthermore, because the medication use in the high- and normal-aldosterone groups was the same, medication-related effects on urinary protein excretion should have been similar.
The current study is also limited by the lack of 24-hour BP measurements. Studies using direct measurements of BP in animals or 24-hour ambulatory BP in humans have shown that elevated systemic BP is a dominant factor in mediating the effects of mineralocorticoid excess on renal function.\textsuperscript{40,41} We have reported recently that ambulatory BP monitoring levels are higher in resistant hypertensive subjects with high compared with normal aldosterone levels in spite of similar office BPs.\textsuperscript{42} Such higher 24-hour BPs would be expected to contribute importantly to the increased proteinuria in the high-aldosterone subjects.

**Perspectives**

Animal studies indicate that aldosterone excess and high dietary salt intake in combination have the most pronounced effects on target-organ deterioration. The current study suggests that a similar interaction may be contributing importantly to proteinuria in humans with resistant hypertension. If confirmed, our findings support the testing of treatment strategies based on dietary salt restriction and the use of mineralocorticoid receptor antagonists to help preserve kidney function in subjects with resistant hypertension.

**Sources of Funding**

This work was supported by National Heart, Lung, and Blood Institute grants HL075614 and SCCOR P50HL077100 received by D.A.C.; National Heart, Lung, and Blood Institute grant HL007457 received by M.N.P-U.; and National Institutes of Health grant HL075614 and SCCOR P50HL077100 received by K.J. Adler. The current study is also limited by the lack of 24-hour ambulatory BP monitoring.

**Disclosures**

None.

**References**


Relation of Dietary Salt and Aldosterone to Urinary Protein Excretion in Subjects With Resistant Hypertension
Eduardo Pimenta, Krishna K. Gaddam, Monique N. Pratt-Ubunama, Mari K. Nishizaka, Inmaculada Aban, Suzanne Oparil and David A. Calhoun

Hypertension. 2008;51:339-344; originally published online December 17, 2007; doi: 10.1161/HYPERTENSIONAHA.107.100701

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2007 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/51/2/339

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/